Edgar Filing: NEOGENOMICS INC - Form 8-K

NEOGENOMICS INC

Form 8-K

October 30, 2018

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 30, 2018

NEOGENOMICS, INC.

(Exact name of registrant as specified in its charter)

Nevada 001-35756 74-2897368
(State or other jurisdiction of File Number) Identification incorporation) No.)

12701

Commonwealth

Drive, Suite 9, 33913

Fort Myers, Florida (Address of

principal (Zip executive Code)

offices)

(239) 768-0600

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR

Edgar Filing: NEOGENOMICS INC - Form 8-K

240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

240.13e-4(c))

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Edgar Filing: NEOGENOMICS INC - Form 8-K

Results of

Operations

Item 2.02 and

Financial

Condition.

On October 30, 2018, NeoGenomics, Inc. (the "Company") issued a press release reporting its results for its third fiscal quarter of 2018. The press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference. This information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and it shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Financial

Item 9.01 Statements

and Exhibits.

- (a) Not applicable
- (b) Not applicable
- (c) Not applicable
- (d) Exhibits.

Press Release of

NeoGenomics,

99.1 Inc. dated

October 30,

2018.

Exhibit Index

Exhibit

No. Description

Press Release of

NeoGenomics.

99.1 Inc. dated

October 30,

<u>2018.</u>

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

NEOGENOMICS,

INC.

By: /s/ Sharon A. Virag

Sharon A Virag

Chief Financial

Officer

October 30, 2018